Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers
Annals of Clinical and Translational Neurology · 2025
DOI: 10.1002/acn3.70033 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Andreas Meier und 8 weiteren Autor:innen. Beteiligte Einrichtung: Formerly Vigil Neuroscience, Inc., Watertown, Massachusetts, USA. Hauptthemen laut MEDLINE: Membrane Glycoproteins, Receptors, Immunologic, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vigil Neuroscience Inc.
Abstract (Originalsprache)
Objective
To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of iluzanebart, a fully human monoclonal antibody TREM2 (triggering receptor expressed on myeloid cells 2) agonist, after single‐ (SAD) and multiple‐ascending‐dose (MAD) administration.
Methods
Healthy adult volunteers ( N = 136) received intravenous placebo or iluzanebart 1–60 mg/kg (SAD) or 10–60 mg/kg (MAD) followed by serial pharmacokinetics and safety assessments. Safety assessments included adverse events (AEs), vital signs, electrocardiograms, and clinical laboratory evaluations. Pharmacokinetics were assessed through noncompartmental analysis. The study also included open‐label cohorts (3, 10, 20, 40, 60 mg/kg SAD; 10, 20, 40 mg/kg MAD) for cerebrospinal fluid (CSF) collection for exploratory pharmacodynamic biomarker analysis.
Results
Iluzanebart was safe and well tolerated following single and multiple doses of up to 60 mg/kg. Most AEs were mild and resolved spontaneously. The most frequently reported AE was pruritus. No serious AEs or investigational product–related clinically meaningful changes in vital signs, electrocardiograms, or laboratory assessments were reported. Iluzanebart serum exposure was related to dose, with a 29‐day half‐life that is supportive of monthly dosing and confirmed central nervous system (CNS) exposure (≈0.15% CSF‐to‐serum ratio). Durable and dose‐dependent target engagement, evidenced by marked reductions in soluble TREM2 and increased soluble CSF1R (colony‐stimulating factor 1 receptor) and osteopontin/SPP1 (secreted phosphoprotein 1) levels in CSF, was observed, indicating that iluzanebart changes microglial activity following single and repeat dosing.
Interpretation
Iluzanebart demonstrated favorable safety, tolerability, pharmacokinetics, and pharmacological activity in the CNS, supporting further clinical development for adult‐onset leukoencephalopathy with axonal spheroids and pigmented glia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Formerly Vigil Neuroscience, Inc., Watertown, Massachusetts, USA.
- Vigil Neuroscience, Inc., Watertown, Massachusetts, USA.
- Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
Förderung
- Vigil Neuroscience Inc
Zitieren
APA
Meier, A., Papapetropoulos, S., Marsh, A., Neelon, K., Stiles, D., O'Mara, R., Thackaberry, E. A., Colonna, M., & Rajagovindan, R. (2025). Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70033
Vancouver
Meier A, Papapetropoulos S, Marsh A, Neelon K, Stiles D, O'Mara R, et al. Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70033
BibTeX
@article{Meier2025,
author = {Meier, Andreas and Papapetropoulos, Spyros and Marsh, Andrew and Neelon, Kelly and Stiles, David and O'Mara, Ryan and Thackaberry, Evan A and Colonna, Marco and Rajagovindan, Raj},
title = {Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
doi = {10.1002/acn3.70033}
}
EUVIMED